AlerGenetica’s Solution/Strategy

AlerGenetica has advanced the approach for treatment of fungal allergy conditions. Our therapeutics will be  based on small proteins (peptides). Peptides can be easily chemically synthesized under pharmaceutical production and quality control conditions to insure composition and purity.

Our candidate  therapeutics do not contain recombinant DNA or other types of proteins as contaminants. Using specific tests, our peptides are assayed for biological activity in representative patient populations.

For use in allergy immunotherapy treatments, peptides can be manufactured and do not contain structures that react with IgE and thus have increased safety. This is predicted to significantly shorten the treatment time and number of treatments needed

University of Manchester

For use in allergy immunotherapy treatments, peptides can be manufactured and do not contain structures that react with IgE and thus have increased safety. This is predicted to significantly shorten the treatment time and number of treatments needed